Abstract
BackgroundFeline Panleukopenia (FPL) is a serious disease of cats that can be prevented by vaccination. Kittens are routinely vaccinated repeatedly during their first months of life. By this time maternally derived antibodies (MDA) can interfere with vaccination and inhibit the development of active immunity. The efficacy of primary vaccination under field conditions was questioned by frequent reports to the Paul-Ehrlich-Institut on outbreaks of FPL in vaccinated breeding catteries. We therefore initiated a field study to investigate the development of immunity in kittens during primary vaccination against FPL.64 kittens from 16 litters were vaccinated against FPL at the age of 8, 12 and 16 weeks using three commercial polyvalent vaccines. Blood samples were taken before each vaccination and at the age of 20 weeks. Sera were tested for antibodies against Feline Panleukopenia Virus (FPV) by hemagglutination inhibition test and serum neutralisation assay in two independent diagnostic laboratories.ResultsThere was a good correlation between the results obtained in different laboratories and with different methods. Despite triple vaccination 36.7% of the kittens did not seroconvert. Even very low titres of MDA apparently inhibited the development of active immunity. The majority of kittens displayed significant titres of MDA at 8 and 12 weeks of age; in some animals MDA were still detected at 20 weeks of age. Interestingly, the vaccines tested differed significantly in their ability to overcome low levels of maternal immunity.ConclusionsIn the given situation it is recommended to quantify antibodies against FPV in the serum of the queen or kittens before primary vaccination of kittens. The beginning of primary vaccination should be delayed until MDA titres have declined. Unprotected kittens that have been identified serologically should be revaccinated.
Highlights
Feline Panleukopenia (FPL) is a serious disease of cats that can be prevented by vaccination
The inter-laboratory variation and predictive values showed a good correlation between methods (HI vs Serumneutralisation tests (SNT): Lab A 0.983 Lab B 0.804) and laboratories (Lab A vs Lab B: hemagglutination inhibition (HI) 0.897 SNT 0.949)
In addition we found a close relationship between antibody titres of the queens and the kinetics of Maternally derived antibodies (MDA) titres in the respective kittens which is in line with previous reports [8]
Summary
Feline Panleukopenia (FPL) is a serious disease of cats that can be prevented by vaccination. Kittens are routinely vaccinated repeatedly during their first months of life By this time maternally derived antibodies (MDA) can interfere with vaccination and inhibit the development of active immunity. Sera were tested for antibodies against Feline Panleukopenia Virus (FPV) by hemagglutination inhibition test and serum neutralisation assay in two independent diagnostic laboratories. Neutropenia and diarrhoea due to Vaccines against FPL are generally based on avirulent, replication competent virus strains (modified live vaccines, MLV). Successful vaccination induces virus-neutralising antibodies that provide protection against clinical FPL [2,57]. They can be used to monitor the immunological status of an animal [8]. After the complete disappearance of MDA a single vaccination with MLV may lead to seroconversion and high, long-lasting titres [13]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
